https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2022-03-21 09:00:262022-08-17 15:23:02Autifony to speak at the Schizophrenia International Research Society (SIRS) meeting in Florence 6 – 10th April
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2021-05-01 09:00:422022-07-22 12:22:16Autifony to speak at ‘Fragile X syndrome webinar – in pursuit of a cure’ World Fragile X Day
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2021-04-16 09:00:212022-08-17 15:31:53Autifony presents key efficacy data for AUT00206 from a first-in-patient safety/PK study in patients with schizophrenia at the Schizophrenia International Research Society annual meeting
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2021-03-04 09:00:362022-05-30 10:20:01Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2020-05-04 09:00:052022-05-30 10:19:37Autifony Therapeutics announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2019-05-30 09:00:412022-05-30 10:25:30Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2019-04-11 09:00:442022-05-30 10:24:32Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2019-01-18 09:00:012022-05-30 11:01:31Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2017-12-18 09:00:492022-08-17 15:15:29Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders